HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India

被引:48
作者
Balakrishnan, P
Kumarasamy, N
Kantor, R
Solomon, S
Vidya, S
Mayer, KH
Newstein, M
Thyagarajan, SP
Katzenstein, D
Ramratnam, B
机构
[1] VHS, YRG, Ctr AIDS Res & Educ, Madras 600113, Tamil Nadu, India
[2] Stanford Univ, Div Infect Dis, Stanford, CA 94305 USA
[3] Brown Univ, Sch Med, Dept Med, Div Infect Dis, Providence, RI 02906 USA
[4] Univ Madras, Dept Microbiol, Madras 600113, Tamil Nadu, India
关键词
D O I
10.1089/aid.2005.21.301
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most studies of HIV-1 drug resistance have examined subtype B viruses; fewer data are available from developing countries, where non-B subtypes predominate. We determined the prevalence of mutations at protease and reverse transcriptase drug resistance positions in antiretroviral drug-naive individuals in southern India. The pol region of the genome was amplified from plasma HIV-1 RNA in 50 patients. All sequences clustered with HIV-1 subtype C. All patients had at least one protease and/or RT mutation at a known subtype B drug resistance position. Twenty percent of patients had mutations at major protease inhibitor resistance positions and 100% had mutations at minor protease inhibitor resistance positions. Six percent and 14% of patients had mutations at nucleoside reverse transcriptase inhibitor and/or nonnucleoside reverse transcriptase inhibitor resistance positions, respectively. Larger scale studies need to be undertaken to better define the genotypic variation of circulating Indian subtype C viruses and their potential impact on drug susceptibility and clinical outcome in treated individuals.
引用
收藏
页码:301 / 305
页数:5
相关论文
共 15 条
[1]   Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults [J].
Becker-Pergola, G ;
Kataaha, P ;
Johnston-Dow, L ;
Fung, S ;
Jackson, JB ;
Eshleman, SH .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (08) :807-813
[2]   HIV-1 drug resistance in newly infected individuals [J].
Boden, D ;
Hurley, A ;
Zhang, LQ ;
Cao, YZ ;
Guo, Y ;
Jones, E ;
Tsay, J ;
Ip, J ;
Farthing, C ;
Limoli, K ;
Parkin, N ;
Markowitz, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141
[3]   pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D [J].
Cornelissen, M ;
vandenBurg, R ;
Zorgdrager, F ;
Lukashov, V ;
Goudsmit, J .
JOURNAL OF VIROLOGY, 1997, 71 (09) :6348-6358
[4]  
DeGruttola V, 2000, ANTIVIR THER, V5, P41
[5]   Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors [J].
Gonzales, MJ ;
Wu, TD ;
Taylor, J ;
Belitskaya, F ;
Kantor, R ;
Israelski, D ;
Chou, S ;
Zolopa, AR ;
Fessel, WJ ;
Shafer, RW .
AIDS, 2003, 17 (06) :791-799
[6]   Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN) [J].
Gonzales, MJ ;
Dugan, JM ;
Shafer, RW .
BIOINFORMATICS, 2002, 18 (06) :886-887
[7]   High resistance to antiretroviral drugs: the Indian experience [J].
Hira, SK ;
Panchal, K ;
Parmar, PA ;
Bhatia, VP .
INTERNATIONAL JOURNAL OF STD & AIDS, 2004, 15 (03) :173-177
[8]   HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy [J].
Kantor, R ;
Zijenah, LS ;
Shafer, RW ;
Mutetwa, S ;
Johnston, E ;
Lloyd, R ;
Von Lieven, A ;
Israelski, D ;
Katzenstein, DA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (18) :1407-1413
[9]  
KANTOR R, 2003, 10 C RETR OPP INF BO
[10]   The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India [J].
Kumarasamy, N ;
Solomon, S ;
Chaguturu, SK ;
Mahajan, AP ;
Flanigan, TP ;
Balakrishnan, P ;
Mayer, KH .
AIDS, 2003, 17 (15) :2267-2269